AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

President Trump spares tariffs on pharmaceuticals, but says that he is worried about supply issues given most drugs in the ...

China on Friday announced the imposition of 34 per cent tariffs on all US goods. In retaliation to US President Donald ...

Total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has risen 66% to $41.5 billion ...

Investing.com -- The latest tariffs imposed by the Trump administration are not a major concern for the China healthcare ...

Click to share on X (Opens in new window) Click to share on LinkedIn (Opens in new window) Click to share on Facebook (Opens in new window) Click to share on Reddit (Opens in new window) Click to ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an initial public offering (IPO) on the week of April 7th, IPO Scoop reports. The company plans to issue 2,700,000 shares at $7.

Pharma and biotech companies are breathing a sigh ... made into drugs consumed in the U.S. Europe made 22%, and China, 13%. Just 10% of APIs in 2021 were manufactured in the U.S. A 2022 evaluation ...

Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical ...

Healthcare and medical manufacturing in Australia is gaining momentum with ASX companies at the forefront of growth.

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Thursday, April 3rd, IPO Scoop reports. The company plans to issue 2,700,000 shares at ...